

Highlights of This Issue 1151

REVIEW

- 1153 | **The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy**
Xuan Pan, Rui Wang, and Zhao-Xia Wang

CHEMICAL THERAPEUTICS


- 1163 | **CXCR4-Targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis**
Xiaojuan Sun, Cherie Charbonneau, Lei Wei, Wentian Yang, Qian Chen, and Richard M. Terek
- 1171 | **CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma**
Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, and James C. Cusack
- 1180 | **Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells**
Alessandra De Robertis, Silvia Valensin, Marco Rossi, Patrizia Tunici, Margherita Verani, Antonella De Rosa, Cinzia Giordano, Maurizio Varrone, Arianna Nencini, Carmela Pratelli, Tiziana Benicchi, Annette Bakker, Jeffrey Hill, Kanda Sangthongpitag, Vishal Pendharkar, Boping Liu, Fui Mee Ng, Siew Wen Then, Shi Jing Tai, Seong-Moon Cheong, Xi He, Andrea Caricasole, and Massimiliano Salerno
- 1190 | **PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer**
Katherine T. Ostapoff, Niranjana Awasthi, Bercin Kutluk Cenic, Stefan Hinz, Keith Dredge, Roderich E. Schwarz, and Rolf A. Brekken

- 1202 | **MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1 α mRNA through Decreasing Nuclear-Cytoplasmic Translocation of RNA-Binding Protein HuR**
Yun-Ching Cheng, Jing-Ping Liou, Ching-Chuan Kuo, Wen-Yang Lai, Kuang-Hsing Shih, Chi-Yen Chang, Wen-Yu Pan, Joseph T. Tseng, and Jang-Yang Chang

LARGE MOLECULE THERAPEUTICS

- 1213 | **IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy**
Charles Ferté, Yohann Loriot, Céline Clémenson, Frederic Commo, Andrea Gombos, Jean-Emmanuel Bibault, Ingrid Fumagalli, Saad Hamama, Nathalie Auger, Benoit Lahon, Cyrus Chargari, Julien Calderaro, Jean-Charles Soria, and Eric Deutsch
- 1223 | **Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells *In Vitro* and *In Vivo***
Filza Hussain, Michael Freissmuth, Dirk Völkel, Michael Thiele, Patrice Douillard, Gerhard Antoine, Patrick Thurner, Hartmut Ehrlich, Hans-Peter Schwarz, Friedrich Scheiflinger, and Randolph J. Kerschbaumer
- 1235 | **Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2-Induced Apoptosis**
Jeffery S. Swers, Luba Grinberg, Lin Wang, Hui Feng, Kristen Lekstrom, Rosa Carrasco, Zhan Xiao, Ivan Inigo, Ching Ching Leow, Herren Wu, David A. Tice, and Manuel Baca
- 1245 | **Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer**
Kilian M. Gust, David J. McConkey, Shannon Awrey, Paul K. Hegarty, Jing Qing, Jolanta Bondaruk, Avi Ashkenazi, Bogdan Czerniak, Colin P. Dinney, and Peter C. Black

- 1255 **DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma**
Dongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall Dere, MaryAnn Go, Jeffrey Lau, Bing Zheng, Kristi Elkins, Dimitry Danilenko, Katherine R. Kozak, Pamela Chan, Josefa Chuh, Xiaoyan Shi, Denise Nazzal, Franklin Fuh, Jacqueline McBride, Vanitha Ramakrishnan, Ruth de Tute, Andy Rawstron, Andrew S. Jack, Rong Deng, Yu-Waye Chu, David Dornan, Marna Williams, William Ho, Allen Ebens, Saileta Prabhu, and Andrew G. Polson

- 1322 **Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model**
 Lotfi Abou-Elkacem, Susanne Arns, Gunnar Brix, Felix Gremse, Dieter Zopf, Fabian Kiessling, and Wiltrud Lederle

- 1332 **Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma**
Matteo S. Carlino, Kavitha Gowrishankar, Catherine A.B. Saunders, Gulietta M. Pupo, Stephanie Snoyman, Xu Dong Zhang, Robyn Saw, Therese M. Becker, Richard F. Kefford, Georgina V. Long, and Helen Rizos

CANCER THERAPEUTICS INSIGHTS

- 1266 **Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation**
Tiffany N. MacKenzie, Nameeta Mujumdar, Sulagna Banerjee, Veena Sangwan, Aaron Sarver, Selwyn Vickers, Subbaya Subramanian, and Ashok K. Saluja

- 1343 **Overlapping Functions of ABC Transporters in Topotecan Disposition as Determined in Gene Knockout Mouse Models**
Amit K. Tiwari, Rong Zhang, and James M. Gallo

- 1276 **Resveratrol Induces Differentiation Markers Expression in Anaplastic Thyroid Carcinoma via Activation of Notch1 Signaling and Suppresses Cell Growth**
Xiao-Min Yu, Renata Jaskula-Sztul, Kamal Ahmed, April D. Harrison, Muthusamy Kunnimalaiyaan, and Herbert Chen

- 1356 **Zoledronic Acid Reverses the Epithelial-Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF- κ B**
Amanda J. Schech, Armina A. Kazi, Rabia A. Gilani, and Angela H. Brodie

- 1288 **REST Negatively and ISGF3 Positively Regulate the Human STAT1 Gene in Melanoma**
James Amalraj, Samuel J. Cutler, Ibtisam Ghazawi, Glen M. Boyle, and Stephen J. Ralph

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 1367 **Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary**
Takeshi Hisamatsu, Seiji Mabuchi, Yuri Matsumoto, Mahiru Kawano, Tomoyuki Sasano, Ryoko Takahashi, Kenjiro Sawada, Kimihiko Ito, Hirohisa Kurachi, Russell J. Schilder, Joseph R. Testa, and Tadashi Kimura

- 1299 **Drug Repurposing for Gastrointestinal Stromal Tumor**
Ziyan Y. Pessetto, Scott J. Weir, Geetika Sethi, Melinda A. Broward, and Andrew K. Godwin


- 1310 **Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1- β -Riboside-Induced Apoptosis in Multiple Myeloma Cells**
Carolyn Bardeleben, Sanjai Sharma, Joseph R. Reeve, Sara Bassilian, Patrick Frost, Bao Hoang, Yijiang Shi, and Alan Lichtenstein

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Hypoxia can drive loss of tumor cell differentiation and elevate metastatic potential in pancreatic cancer. Inhibition of heparanase with PG545 reduced vascular function and increased hypoxia in a GEMM of pancreatic cancer; however, PG545 treatment did not enhance tumor cell EMT. Immunofluorescence was used to show that tumors from PG545-treated animals express elevated levels of membrane-associated β -catenin, a characteristic of epithelial cells. These data are consistent with observed changes in E-cadherin and other EMT-associated proteins and suggest that the proinvasive effects of hypoxia can be abrogated by inhibition of heparanase. For details, see article by Ostapoff and colleagues on page 1190.



Molecular Cancer Therapeutics

12 (7)

Mol Cancer Ther 2013;12:1151-1377.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/12/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/12/7>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.